Loading
Surgeon who chairs the NRG Oncology breast committee and co-led the KATHERINE and B-42 trials.
Eleftherios Mamounas (Orlando Health) chairs the NRG Oncology Breast Committee and was NSABP protocol chair for B-42 (extended letrozole) and co-chair of KATHERINE, which established adjuvant T-DM1 for residual disease after neoadjuvant therapy. He has led work using the 21-gene assay to predict locoregional recurrence and radiotherapy benefit. His current trials test omission of surgery and radiotherapy after excellent neoadjuvant response.
Shares KATHERINE, KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Trastuzumab emtansine, HER2-positive breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags breast, surgery.
Shares HR-positive / HER2-negative breast cancer and the tags breast, surgery.
Shares KATHERINE, KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Trastuzumab emtansine, HER2-positive breast cancer.
Shares Trastuzumab emtansine, HER2-positive breast cancer and the tag breast.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag breast.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag breast.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag breast.